Genetically modified bacteria and methods for genetic modification of bacteria
Microbes can be genetically modified to express biomolecules that are beneficial to mammals and/or to reduce, or eliminate, expression of harmful virulence factors. The growth and viability of such genetically modified microbes can optionally be controlled by inducible promoters that regulate the expression of proteins that are essential to their growth and survival. Compositions comprising such genetically modified microbes as well as methods of making and using the same are disclosed herein.
1. A method for treating acne, atopic dermatitis, or psoriasis in a mammal in need thereof, the method comprising contacting the skin of the mammal with a pharmaceutical composition comprising a genetically modified Propionibacterium acnes ( P. acnes ) strain comprising a regulatory element operably linked to a nucleic acid encoding a mammalian anti-inflammatory cytokine comprising interleukin-10 (IL-10), wherein the strain expresses the mammalian anti-inflammatory cytokine, the P. acnes strain comprises a CRISPR array, and the regulatory element and the nucleic acid are integrated into the genome of the P. acnes strain.
2. The method of claim 1 , wherein the mammalian anti-inflammatory cytokine is a human cytokine.
3. The method of claim 1 , wherein the IL-10 comprises the amino acid sequence of SEQ ID NO:25.
4. The method of claim 1 , wherein the P. acnes further comprises an inducible promoter operably linked to a gene expressing an essential protein, wherein the gene is endogenous to the P. acnes strain and the essential protein is essential for growth or viability of the P. acnes strain.
5. The method of claim 4 , wherein the essential protein is selected from the group consisting of DnaA, FtsA, FtsI, FtsL, FtsK, FtsN, FtsQ, FtsW, FtsZ, ZipA, aroE, atpD, gmk, guaA, lepA, recA, and sodA.
6. The method of claim 4 , wherein the inducible promoter is regulated by a sugar selected from lactose or arabinose.
7. The method of claim 4 , wherein the inducible promoter is regulated by an amino acid or a synthetic amino acid.
8. The method of claim 4 , wherein the essential protein is a chromosome replication initiator protein.
9. A method for treating acne, atopic dermatitis, or psoriasis in a mammal in need thereof, the method comprising contacting the skin of the mammal with a pharmaceutical composition comprising a genetically modified Propionibacterium acnes ( P. acnes ) strain comprising a regulatory element operably linked to a nucleic acid encoding a mammalian anti-inflammatory cytokine comprising interleukin-10 (IL-10), wherein the P. acnes strain expresses the mammalian anti-inflammatory cytokine, and wherein the P. acnes strain is P. acnes , type II, ribotype 6.
10. The method of claim 9 , wherein expression of a pathogenic protein within the P. acnes is substantially reduced or eliminated.
11. The method of claim 10 , wherein the pathogenic protein comprises an endotoxin, an exotoxin, a glyceraldehyde 3-phosphate dehydrogenase (GADPH) protein, or a CAMP protein.
12. The method of claim 9 , wherein the mammalian anti-inflammatory cytokine is a human cytokine.
13. The method of claim 9 , wherein the IL-10 comprises the amino acid sequence of SEQ ID NO:25.
14. The method of claim 9 , wherein the P. acnes strain further comprises an inducible promoter operably linked to a gene expressing an essential protein, wherein the gene is endogenous to the P. acnes strain and the essential protein is essential for growth or viability of the P. acnes strain.
15. The method of claim 9 , wherein the regulatory element is a bacterial promoter that is endogenous to the genetically modified bacteria, the bacterial promoter comprising a lacZ promoter, lacZ operon, or an ara operon promoter.
16. The method of claim 9 , wherein the nucleic acid encoding the mammalian anti-inflammatory cytokine is inserted into all or a part of a P. acnes gene that encodes a pathogenic protein, wherein the P. acnes gene is endogenous to the genetically modified P. acnes.
17. The method of claim 9 , wherein expression of an endogenous P. acnes protein is substantially reduced or eliminated.
18. The method of claim 9 , wherein the pharmaceutical composition is contacted with the skin of the mammal through topical administration to the mammal.
19. The method of claim 9 , wherein the pharmaceutical composition is in the form of a gel formulation, a cream formulation, a lotion formulation, a paste formulation, an ointment formulation, an oil formulation, or a foam formulation for topical administration to the mammal.
20. The method of claim 9 , wherein the mammal is a human, dog, or cat.